The Effect of Recognition and Expression of Emotions Program Applied to Schizophrenia Patients

Sponsor
Sinop University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05662137
Collaborator
(none)
44
1
2
7
6.3

Study Details

Study Description

Brief Summary

As a result of the positive and negative symptoms that occur in schizophrenia, patients with schizophrenia may experience negative emotions more frequently than individuals with other mental problems. Since these emotions can trigger psychotic symptoms, there is a need to develop effective emotion regulation strategies to be applied to patients with schizophrenia.

Aim: In this study, it was aimed to examine the effect of emotion recognition and expression program on alexithymia and emotion expression in patients with schizophrenia.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Emotions Recognition and Expression
N/A

Detailed Description

Method: Fifty schizophrenic patients who regularly receive outpatient treatment at Sinop Community Mental Health Center will form the universe of the study. Individuals over the age of 18 who have schizophrenia, do not have mental retardation, have no comprehension and hearing problems, have insight, and are in remission will be included in the study. Individuals who meet the study criteria will be divided into experimental and control groups as 22 experimental and 22 control groups. The emotion recognition and expression program prepared by the researchers in line with the literature will be applied to the experimental group for 8 weeks. Personal Information Form, Expression of Emotions Scale, Positive and Negative Syndrome Scale and Toronto Alexithymia Scale were planned to be applied to the experimental and control groups in the pre-test, post-test and follow-up. Follow-up will take place one month after the last session of the study. Psychosocial interventions applied to patients with schizophrenia help patients to increase their level of well-being and quality of life, to decrease negative and positive symptoms by increasing social functionality, to participate in social life, to be an autonomous individual and to prevent stigma. In line with psychosocial interventions, it is thought that the this program to be applied to the patients in this study will basically contribute to the individual patients' ability to recognize their emotions, discuss their emotions, regulate their emotion intensities, and express their emotions. Due to the impact that this program will have on the individual, it is believed that it will have positive results not only for schizophrenia patients, but also for the individuals with whom the patients interact, their relatives and even the society.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
44 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Care Provider, Investigator)
Primary Purpose:
Supportive Care
Official Title:
The Effect of Recognition and Expression of Emotions Program Applied to Schizophrenia Patients Applying to Community Mental Health Center on Alexithymia and Emotion Expression
Anticipated Study Start Date :
Jan 15, 2023
Anticipated Primary Completion Date :
Mar 15, 2023
Anticipated Study Completion Date :
Aug 15, 2023

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control group

At the beginning of the study, data collection tools Personal Information Form, Expression of Emotions Scale, Toronto Alexithymia Scale, Positive and Negative Syndrome Scale will be applied to the control group. No intervention will be made in the control group. Measurement tools will be applied for the posttest. Emotional Expression Scale, Toronto Alexithymia Scale and Positive and Negative Syndrome Scale will be reapplied 1 month after the last session.

Experimental: Experimental group

Emotion recognition and expression program is aimed to be carried out in 8-week sessions for schizophrenia patients included in the experimental group. Personal Information Form, Expression of Emotions Scale, Toronto Alexithymia Scale, Positive and Negative Syndrome Scale will be applied to the experiment. The principal investigator will lead the structured group sessions as the group leader. The principal investigator will lead the structured group sessions as the group leader. Each group is planned to be 60-90 minutes. Before sessions, participants are taken from their previous session's emotions so far. Homework is discussed by providing recall of the topic from the previous session, and then the current topic is moved on. At the end of each session, a general summary and evaluation is made. After the sessions in the research, measurement tools will be applied for the posttest. It will be reapplied 1 month after the last session.

Behavioral: Emotions Recognition and Expression
Emotion recognition and expression program consisting of 8 sessions will be used. In this program, patients will have the opportunity to describe their emotions, explain emotions that are difficult to express such as anger, sadness, shame, guilt, and discuss the consequences of suppressed emotions.

Outcome Measures

Primary Outcome Measures

  1. Emotion Recognition and Expression [One day]

    Expression of Emotions Scale is used to measure the state of expression of emotions. The scale was developed by King and Emmons (1990), and its Turkish validity and reliability were verified by Kuzucu (2011). The measurement tool consists of a total of 16 items and 3 sub-dimensions. It has positive, negative and closeness sub-dimensions. It is a 7-point Likert type scale .The scores to be taken from the scale vary between 15 and 105, and as the scores obtained increase, it is seen that the tendency of the individual to express emotion increases. The scale provides information about expressing emotions both in interpersonal relationships and independent of interpersonal relationships. A high score indicates a high tendency to express emotions.

  2. Alexithymia [One day]

    Toronto Alexithymia Scale (TAS): The scale was developed by Bagby et al. (1994) Güleç et al. (2009) adapted into Turkish. The scale consists of 20 items, has three sub-dimensions and is in a 5-point Likert type. High scores indicate high alexithymic level. There are sub-dimensions of difficulty in recognizing emotions, difficulty in putting emotions into words, and extroverted thinking.

  3. Positive and Negative Syndrome [One day]

    Positive and Negative Syndrome Scale (PANNS): The scale evaluating positive and negative symptoms in schizophrenia was developed by Kay et al (1987) and Kostakoğlu et al. It was adapted into Turkish by (1999). Consisting of 30 items, the scale has three sub-dimensions. A 7-point severity assessment is carried out. Seven of the items of the scale belong to the positive symptoms subscale, seven to the negative symptoms subscale, and the remaining sixteen to the general psychopathology subscale.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient who had received a diagnosis of schizophrenia and comes to the Community Mental Health Center regularly,

  • Being able to read and communicate

  • Being 18 years of age or older,

  • Not having mental retardation,

  • Not having insight, understanding, hearing problems,

  • Being in remission,

  • Volunteering to study

Exclusion Criteria:
  • Not diagnosed with clinical schizophrenia,

  • Being under the age of 18,

  • Having mental retardation,

  • Having no insight,

  • Not understanding and hearing,

  • Not in remission

  • Refusing to participate in the study

  • Stop studying at any stage of the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sinop Community Mental Health Center Sinop Turkey 57000

Sponsors and Collaborators

  • Sinop University

Investigators

  • Principal Investigator: Adeviye AYDIN, PhD, Sinop University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sinop University
ClinicalTrials.gov Identifier:
NCT05662137
Other Study ID Numbers:
  • sınopUadeviye-1
First Posted:
Dec 22, 2022
Last Update Posted:
Dec 27, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Sinop University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 27, 2022